Cargando…
Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma
SIMPLE SUMMARY: The escalating use of Next Generation Sequencing in the routine clinical setting greatly facilitates the genetic diagnosis of hereditary cancer syndromes. However, these novel methods pose new and unique challenges. In our study we sought to demonstrate the evolution of these techniq...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392134/ https://www.ncbi.nlm.nih.gov/pubmed/34439371 http://dx.doi.org/10.3390/cancers13164219 |
_version_ | 1783743430687457280 |
---|---|
author | Sarkadi, Balazs Liko, Istvan Nyiro, Gabor Igaz, Peter Butz, Henriett Patocs, Attila |
author_facet | Sarkadi, Balazs Liko, Istvan Nyiro, Gabor Igaz, Peter Butz, Henriett Patocs, Attila |
author_sort | Sarkadi, Balazs |
collection | PubMed |
description | SIMPLE SUMMARY: The escalating use of Next Generation Sequencing in the routine clinical setting greatly facilitates the genetic diagnosis of hereditary cancer syndromes. However, these novel methods pose new and unique challenges. In our study we sought to demonstrate the evolution of these techniques, especially whole exome sequencing and targeted panel sequencing. This study highlights the multi-layered workflow and how each step affects the diagnostic outcome and demonstrates the effectiveness of an in-house developed targeted panel sequencing for hereditary endocrine tumor syndromes. ABSTRACT: Next Generation Sequencing (NGS)-based methods are high-throughput and cost-effective molecular genetic diagnostic tools. Targeted gene panel and whole exome sequencing (WES) are applied in clinical practice for assessing mutations of pheochromocytoma/paraganglioma (PPGL) associated genes, but the best strategy is debated. Germline mutations of at the least 18 PPGL genes are present in approximately 20–40% of patients, thus molecular genetic testing is recommended in all cases. We aimed to evaluate the analytical and clinical performances of NGS methods for mutation detection of PPGL-associated genes. WES (three different library preparation and bioinformatics workflows) and an in-house, hybridization based gene panel (endocrine-onco-gene-panel- ENDOGENE) was evaluated on 37 (20 WES and 17 ENDOGENE) samples with known variants. After optimization of the bioinformatic workflow, 61 additional samples were tested prospectively. All clinically relevant variants were validated with Sanger sequencing. Target capture of PPGL genes differed markedly between WES platforms and genes tested. All known variants were correctly identified by all methods, but methods of library preparations, sequencing platforms and bioinformatical settings significantly affected the diagnostic accuracy. The ENDOGENE panel identified several pathogenic mutations and unusual genotype–phenotype associations suggesting that the whole panel should be used for identification of genetic susceptibility of PPGL. |
format | Online Article Text |
id | pubmed-8392134 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83921342021-08-28 Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma Sarkadi, Balazs Liko, Istvan Nyiro, Gabor Igaz, Peter Butz, Henriett Patocs, Attila Cancers (Basel) Article SIMPLE SUMMARY: The escalating use of Next Generation Sequencing in the routine clinical setting greatly facilitates the genetic diagnosis of hereditary cancer syndromes. However, these novel methods pose new and unique challenges. In our study we sought to demonstrate the evolution of these techniques, especially whole exome sequencing and targeted panel sequencing. This study highlights the multi-layered workflow and how each step affects the diagnostic outcome and demonstrates the effectiveness of an in-house developed targeted panel sequencing for hereditary endocrine tumor syndromes. ABSTRACT: Next Generation Sequencing (NGS)-based methods are high-throughput and cost-effective molecular genetic diagnostic tools. Targeted gene panel and whole exome sequencing (WES) are applied in clinical practice for assessing mutations of pheochromocytoma/paraganglioma (PPGL) associated genes, but the best strategy is debated. Germline mutations of at the least 18 PPGL genes are present in approximately 20–40% of patients, thus molecular genetic testing is recommended in all cases. We aimed to evaluate the analytical and clinical performances of NGS methods for mutation detection of PPGL-associated genes. WES (three different library preparation and bioinformatics workflows) and an in-house, hybridization based gene panel (endocrine-onco-gene-panel- ENDOGENE) was evaluated on 37 (20 WES and 17 ENDOGENE) samples with known variants. After optimization of the bioinformatic workflow, 61 additional samples were tested prospectively. All clinically relevant variants were validated with Sanger sequencing. Target capture of PPGL genes differed markedly between WES platforms and genes tested. All known variants were correctly identified by all methods, but methods of library preparations, sequencing platforms and bioinformatical settings significantly affected the diagnostic accuracy. The ENDOGENE panel identified several pathogenic mutations and unusual genotype–phenotype associations suggesting that the whole panel should be used for identification of genetic susceptibility of PPGL. MDPI 2021-08-22 /pmc/articles/PMC8392134/ /pubmed/34439371 http://dx.doi.org/10.3390/cancers13164219 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sarkadi, Balazs Liko, Istvan Nyiro, Gabor Igaz, Peter Butz, Henriett Patocs, Attila Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma |
title | Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma |
title_full | Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma |
title_fullStr | Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma |
title_full_unstemmed | Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma |
title_short | Analytical Performance of NGS-Based Molecular Genetic Tests Used in the Diagnostic Workflow of Pheochromocytoma/Paraganglioma |
title_sort | analytical performance of ngs-based molecular genetic tests used in the diagnostic workflow of pheochromocytoma/paraganglioma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392134/ https://www.ncbi.nlm.nih.gov/pubmed/34439371 http://dx.doi.org/10.3390/cancers13164219 |
work_keys_str_mv | AT sarkadibalazs analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma AT likoistvan analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma AT nyirogabor analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma AT igazpeter analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma AT butzhenriett analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma AT patocsattila analyticalperformanceofngsbasedmoleculargenetictestsusedinthediagnosticworkflowofpheochromocytomaparaganglioma |